| 1 60‐day mortality |
14 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.1 Aprotinin versus control |
3 |
280 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.52 [0.18, 1.45] |
| 1.2 Tranexamic acid versus control |
3 |
139 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.17, 1.76] |
| 1.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.13, 3.94] |
| 1.4 Antithrombin III versus control |
1 |
29 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.24 [0.01, 4.65] |
| 1.5 Recombinant factor VIIa (rFVIIa) versus control |
3 |
286 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.51 [0.33, 6.95] |
| 1.6 Aprotinin: bolus versus continuous infusion |
1 |
23 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 1.7 Solvent detergent plasma versus standard fresh frozen plasma |
1 |
25 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 1.8 Tranexamic acid versus EACA |
1 |
84 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.21, 4.67] |
| 1.9 Tranexamic acid versus aprotinin |
2 |
178 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.12 [0.71, 23.76] |
| 2 Mortality at maximal follow‐up |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 2.1 Antithrombin III versus control |
1 |
29 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.25 [0.03, 1.85] |
| 2.2 Thromboelastography versus control |
1 |
28 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.13, 3.40] |
| 3 Primary graft non‐function |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 3.1 Aprotinin versus control |
2 |
217 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.15 [0.02, 1.25] |
| 3.2 Tranexamic acid versus control |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.13, 68.57] |
| 3.3 Recombinant factor VIIa (rFVIIa) versus control |
1 |
20 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 4 Retransplantation |
7 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 Aprotinin versus control |
2 |
217 |
Risk Ratio (M‐H, Random, 95% CI) |
0.21 [0.02, 1.79] |
| 4.2 Tranexamic acid versus control |
2 |
77 |
Risk Ratio (M‐H, Random, 95% CI) |
0.79 [0.18, 3.48] |
| 4.3 Prostaglandin versus control |
1 |
20 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 4.4 Aprotinin: bolus versus continuous infusion |
1 |
23 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.05, 10.85] |
| 4.5 Tranexamic acid versus aprotinin |
1 |
127 |
Risk Ratio (M‐H, Random, 95% CI) |
2.95 [0.12, 71.17] |
| 5 Thromboembolic episodes |
12 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.1 Aprotinin versus control |
3 |
280 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.60 [0.18, 1.96] |
| 5.2 Tranexamic acid versus control |
5 |
179 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.20 [0.38, 12.64] |
| 5.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.09, 9.89] |
| 5.4 Recombinant factor VIIa (rFVIIa) versus control |
2 |
266 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.38 [0.65, 2.91] |
| 5.5 Tranexamic acid versus EACA |
1 |
84 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.0 [0.39, 10.34] |
| 5.6 Tranexamic acid versus aprotinin |
2 |
178 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.97 [0.37, 10.37] |
| 6 Serious adverse events |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6.1 Aprotinin versus control |
1 |
137 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.49, 2.11] |
| 6.2 Recombinant factor VIIa (rFVIIa) versus control |
2 |
266 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [0.94, 1.78] |
| 6.3 Low central venous pressure versus control |
1 |
86 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.55, 0.92] |
| 7 Blood loss |
11 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 7.1 Aprotinin versus control |
3 |
195 |
Mean Difference (IV, Random, 95% CI) |
‐1.36 [‐3.39, 0.66] |
| 7.2 Tranexamic acid versus control |
2 |
65 |
Mean Difference (IV, Random, 95% CI) |
‐4.98 [‐10.18, 0.23] |
| 7.3 Antithrombin III versus control |
1 |
29 |
Mean Difference (IV, Random, 95% CI) |
1.9 [‐4.86, 8.66] |
| 7.4 Thromboelastography versus control |
2 |
62 |
Mean Difference (IV, Random, 95% CI) |
‐1.13 [‐1.85, ‐0.41] |
| 7.5 Low central venous pressure versus control |
1 |
86 |
Mean Difference (IV, Random, 95% CI) |
‐1.19 [‐1.88, ‐0.50] |
| 7.6 Tranexamic acid versus aprotinin |
2 |
71 |
Mean Difference (IV, Random, 95% CI) |
‐1.01 [‐2.31, 0.29] |
| 8 Red‐cell or whole blood transfusion |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 8.1 Aprotinin versus control |
1 |
80 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.40, 1.18] |
| 8.2 Tranexamic acid versus control |
1 |
62 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.77 [0.60, 0.98] |
| 8.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.77, 1.06] |
| 8.4 Recombinant factor VIIa (rFVIIa) versus control |
1 |
182 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.86, 0.97] |
| 8.5 Tranexamic acid versus EACA |
1 |
84 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.64, 1.02] |
| 8.6 Tranexamic acid versus aprotinin |
1 |
127 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.71, 1.23] |
| 9 Red cell or whole blood transfusion |
29 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 9.1 Aprotinin versus control |
8 |
375 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.61 [‐0.82, ‐0.40] |
| 9.2 Tranexamic acid versus control |
4 |
159 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.27 [‐0.59, 0.06] |
| 9.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.17 [‐0.71, 0.36] |
| 9.4 Antithrombin III versus control |
1 |
29 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.04 [‐0.77, 0.69] |
| 9.5 Recombinant factor VIIa (rFVIIa) versus control |
2 |
221 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.05 [‐0.32, 0.23] |
| 9.6 Oestrogen versus control |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.58 [‐1.32, 0.15] |
| 9.7 Prostaglandin versus control |
1 |
20 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.04 [‐0.92, 0.83] |
| 9.8 Norepinephrine versus control |
1 |
65 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.04 [‐0.53, 0.44] |
| 9.9 Thromboelastography versus control |
2 |
62 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.73 [‐1.25, ‐0.20] |
| 9.10 Low central venous pressure versus control |
1 |
86 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.17 [‐1.62, ‐0.71] |
| 9.11 Aprotinin: bolus versus continuous infusion |
1 |
23 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.86 [‐0.00, 1.73] |
| 9.12 Aprotinin: high dose versus medium dose |
1 |
189 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.16 [‐0.12, 0.45] |
| 9.13 Aprotinin: high dose versus low dose |
1 |
20 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.46 [‐2.47, ‐0.45] |
| 9.14 Whole blood versus blood components |
1 |
33 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.04 [‐0.72, 0.65] |
| 9.15 Solvent detergent plasma versus standard fresh frozen plasma |
1 |
25 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.19 [‐0.60, 0.98] |
| 9.16 Tranexamic acid versus EACA |
1 |
84 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.23 [‐0.66, 0.20] |
| 9.17 Tranexamic acid versus aprotinin |
3 |
198 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.09 [‐0.36, 0.19] |
| 10 Platelet transfusion |
21 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 10.1 Aprotinin versus control |
5 |
185 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.44 [‐0.73, ‐0.14] |
| 10.2 Tranexamic acid versus control |
4 |
159 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.17 [‐0.49, 0.16] |
| 10.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.01 [‐0.52, 0.55] |
| 10.4 Antithrombin III versus control |
1 |
29 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐0.73, 0.73] |
| 10.5 Recombinant factor VIIa (rFVIIa) versus control |
2 |
216 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.03 [‐0.31, 0.25] |
| 10.6 Oestrogen versus control |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.53 [‐1.26, 0.20] |
| 10.7 Norepinephrine versus control |
1 |
65 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.34 [‐0.15, 0.83] |
| 10.8 Thromboelastography versus control |
1 |
28 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.17 [‐0.91, 0.58] |
| 10.9 Aprotinin: high dose versus medium dose |
1 |
189 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.48 [‐0.77, ‐0.19] |
| 10.10 Whole blood versus blood components |
1 |
33 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.12 [‐0.81, 0.56] |
| 10.11 Solvent detergent plasma versus standard fresh frozen plasma |
1 |
25 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.07 [‐0.71, 0.86] |
| 10.12 Tranexamic acid versus EACA |
1 |
84 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.05 [‐0.37, 0.48] |
| 10.13 Tranexamic acid versus aprotinin |
3 |
198 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.08 [‐0.36, 0.20] |
| 11 Plasma transfusion |
25 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 11.1 Aprotinin versus control |
8 |
420 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.33 [‐0.53, ‐0.13] |
| 11.2 Tranexamic acid versus control |
4 |
159 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.21 [‐0.53, 0.11] |
| 11.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.12 [‐0.66, 0.41] |
| 11.4 Antithrombin III versus control |
1 |
29 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.04 [‐0.69, 0.77] |
| 11.5 Recombinant factor VIIa (rFVIIa) versus control |
2 |
262 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.01 [‐0.28, 0.25] |
| 11.6 Oestrogen versus control |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.67 [‐1.41, 0.07] |
| 11.7 Prostaglandin versus control |
1 |
20 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐0.88, 0.88] |
| 11.8 Norepinephrine versus control |
1 |
65 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.11 [‐0.38, 0.60] |
| 11.9 Thromboelastography versus control |
1 |
28 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.82 [‐1.60, ‐0.05] |
| 11.10 Aprotinin: bolus versus continuous infusion |
1 |
23 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.05 [‐0.78, 0.87] |
| 11.11 Aprotinin: high dose versus medium dose |
1 |
189 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.06 [‐0.22, 0.35] |
| 11.12 Aprotinin: high dose versus low dose |
1 |
20 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.31 [‐2.29, ‐0.32] |
| 11.13 Whole blood versus blood components |
1 |
33 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.53 [‐2.32, ‐0.74] |
| 11.14 Tranexamic acid versus EACA |
1 |
84 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.22 [‐0.65, 0.21] |
| 11.15 Tranexamic acid versus aprotinin |
2 |
71 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.02 [‐0.45, 0.48] |
| 12 Cryoprecipitate |
12 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 12.1 Aprotinin versus control |
3 |
147 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.49 [‐0.82, ‐0.16] |
| 12.2 Tranexamic acid versus control |
4 |
181 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.27 [‐0.57, 0.02] |
| 12.3 Epsilon amino caproic acid (EACA) versus control |
1 |
62 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.00 [‐0.53, 0.54] |
| 12.4 Antithrombin III versus control |
1 |
29 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐0.73, 0.73] |
| 12.5 Oestrogen versus control |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐0.72, 0.72] |
| 12.6 Thromboelastography versus control |
1 |
28 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.25 [1.00, 0.49] |
| 12.7 Whole blood versus blood components |
1 |
33 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.28 [‐0.97, 0.41] |
| 12.8 Solvent detergent plasma versus standard fresh frozen plasma |
1 |
25 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.10 [‐0.68, 0.89] |
| 12.9 Tranexamic acid versus EACA |
1 |
62 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.15 [‐0.69, 0.38] |
| 13 Hospital stay |
6 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 13.1 Aprotinin versus control |
1 |
63 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐4.94, 4.94] |
| 13.2 Tranexamic acid versus control |
1 |
45 |
Mean Difference (IV, Fixed, 95% CI) |
4.0 [‐16.18, 24.18] |
| 13.3 Recombinant factor VIIa (rFVIIa) versus control |
1 |
180 |
Mean Difference (IV, Fixed, 95% CI) |
3.40 [‐7.51, 14.31] |
| 13.4 Norepinephrine versus control |
1 |
65 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.00 [‐3.18, 1.18] |
| 13.5 Low central venous pressure versus control |
1 |
86 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐19.43, 19.43] |
| 13.6 Tranexamic acid versus aprotinin |
1 |
51 |
Mean Difference (IV, Fixed, 95% CI) |
5.0 [‐2.69, 12.69] |
| 14 Intensive therapy unit stay |
9 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 14.1 Aprotinin versus control |
2 |
199 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.21 [‐0.78, 0.36] |
| 14.2 Tranexamic acid versus control |
1 |
45 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.0 [‐4.75, 2.75] |
| 14.3 Recombinant factor VIIa (rFVIIa) versus control |
2 |
199 |
Mean Difference (IV, Fixed, 95% CI) |
0.22 [‐0.14, 0.58] |
| 14.4 Norepinephrine versus control |
1 |
65 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.13 [‐1.65, 1.39] |
| 14.5 Low central venous pressure versus control |
1 |
86 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.0 [‐3.71, 1.71] |
| 14.6 Aprotinin: bolus versus continuous infusion |
1 |
23 |
Mean Difference (IV, Fixed, 95% CI) |
2.0 [‐3.99, 7.99] |
| 14.7 Tranexamic acid versus aprotinin |
1 |
51 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐2.40, 2.40] |
